WHO’s Vax Advisory—Monovalent XBB.1.5 Vaccines Are Sufficient for Now

The World Health Organization (WHO) published a position statement on the COVID-19 vaccines, their effectiveness and more. Citing the ongoing circulation and evolution of SARS-CoV-2 worldwide, with important genetic and antigenic changes concerning the spike protein, WHO reports the monovalent XBB.1.5 vaccines across different platforms (e.g., Pfizer, Moderna, etc.) “Elicit broadly cross-reactive neutralizing antibody responses against circulating SARS-CoV-2 variants.”  Importantly, WHO’s Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC) continues to advise that governments should retain the present COVID-19 vaccine antigen composition, meaning the monovalent XBB.1.5 as the current COVID-19 vaccine antigen.

TrialSite shares WHO’s purported evidence for this position.